Boron Accumulation in Brain Tumor Cells through Boc-Protected Tryptophan as a Carrier for Boron Neutron Capture Therapy

Chio, Chun-Ming; Huang, Ya-Ling; Chou, You-Cheng; Hsu, F.Y.; Lai, Yen-Buo; Yu, Chung‐Shan

doi:10.1021/acsmedchemlett.0c00064

Cited by 12 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, novel approaches to incorporating boron into a natural amino acid, tryptophan, have been developed [ 129 ]. Most recently, a series of protected tryptophan derivatives 41 – 46 ( Scheme 8 ) were synthesized and tested for their capability to accumulate boron into tumor cells and effects on LAT1 expression ( Table S2 , entries 5, 8 and Table S3 , entry 9) [ 130 ].…”

Section: Discussionmentioning

confidence: 99%

Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT)

Järvinen,

Pulkkinen,

Rautio

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Interest in the design of boronated amino acids has emerged, partly due to the utilization of boronophenylalanine (BPA), one of the two agents employed in clinical Boron Neutron Capture Therapy (BNCT). The boronated amino acids synthesized thus far for BNCT investigations can be classified into two categories based on the source of boron: boronic acids or carboranes. Amino acid-based boron carriers, employed in the context of BNCT treatment, demonstrate significant potential in the treatment of challenging tumors, such as those located in the brain. This review aims to shed light on the developmental journey and challenges encountered over the years in the field of amino acid-based boron delivery compound development. The primary focus centers on the utilization of the large amino acid transporter 1 (LAT1) as a target for boron carriers in BNCT. The development of efficient carriers remains a critical objective, addressing challenges related to tumor specificity, effective boron delivery, and rapid clearance from normal tissue and blood. LAT1 presents an intriguing and promising target for boron delivery, given its numerous characteristics that make it well suited for drug delivery into tumor tissues, particularly in the case of brain tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT)

Järvinen,

Pulkkinen,

Rautio

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…(3) Highly boron enriched peptide 25,26 Uptake by specific transport (i.e., LAT1). 21,22,105 Carbohydrates (1) High uptake 24,57,[59][60][61] ;…”

Section: Aminoacids/ Peptidementioning

confidence: 99%

Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment

Coghi

Hosmane

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is one of the most promising treatments among neutron capture therapies due to its long‐term clinical application and unequivocally obtained success during clinical trials. Boron drug and neutron play an equivalent crucial role in BNCT. Nevertheless, current clinically used l‐boronophenylalanine (BPA) and sodium borocaptate (BSH) suffer from large uptake dose and low blood to tumor selectivity, and that initiated overwhelm screening of next generation of BNCT agents. Various boron agents, such as small molecules and macro/nano‐vehicles, have been explored with better success. In this featured article, different types of agents are rationally analyzed and compared, and the feasible targets are shared to present a perspective view for the future of BNCT in cancer treatment. This review aims at summarizing the current knowledge of a variety of boron compounds, reported recently, for the application of BCNT.

show abstract

“…Its herbicidal performance has been demonstrated and the unique 4-nitroindole structure acts as an essential moiety for the phytotoxicity [ 10 ]. In addition, L-4-nitro-Trp also has been used as an intermediate in organic reactions for synthesizing chemicals like triboc-6-boronopinacol tryptophan (TB-6-BT), which has potential for tumor treatment together with other drugs [ 11 ].…”

Section: Introductionmentioning

confidence: 99%